De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma

New research: De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma: Purpose Despite the success of targeted therapy in c-ros oncogene 1 (ROS1)-rearranged cancers, especially… https://t.